Follow us

Events

Braemar (BMS) Full Year results webinar

Tuesday, 28 May, 1:00pm
Register For Event

Braemar CEO,  James Gundy, CFO, Grant Foley and COO, Tris Simmonds will present the Group’s results for full year 2024, followed by a Q&A session.

Braemar provides expert investment, chartering, and risk management advice that enable its clients to secure sustainable returns and mitigate risk in the volatile world of shipping and energy. Our experienced brokers work in tandem with specialist professionals to form teams tailored to our customers’ needs, and provide an integrated service supported by a collaborative culture.

Braemar joined the Official List of the London Stock Exchange in November 1997 and trades under the symbol BMS.

For more information, including our investor presentation, visit www.Braemar.com and follow Braemar on LinkedIn.

Poolbeg Pharma (POLB) Investor webinar

Thursday, 20 June, 2:00pm
Register For Event

Poolbeg Pharma Chief Executive Officer, Jeremy Skillington and Chief Business Officer, David Allmond will host an investor presentation, followed by a Q&A session.

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt’s success and generating near term revenues.

Poolbeg’s clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal. 

For more information, please go to www.poolbegpharma.com

Eneraqua Technologies (ETP) Full Year results webinar

Thursday, 23 May, 11:30am
Register For Event

THIS EVENT HAS PASSED

Eneraqua Technologies CEO, Mitesh Dhanak and CFO, Iain Richardson will host an online investor presentation of the group’s results for the year ended 31 January 2024, followed by a Q&A session.

Eneraqua Technologies (AIM:ETP) is a specialist in energy and water efficiency. The Group has two divisions energy and water. Energy is the larger division, with the Company focused on clients with end of life gas, oil or electric heating and hot water systems. The Group provides turnkey retrofit district or communal heating systems based either on high-efficiency gas or ground/air source heat pump solutions that support Net Zero and decarbonisation goals.

The water division is a growing service offering focused on water efficiency upgrades for utilities and commercial clients including hotels and care homes.

The activities in both divisions are underpinned by the Company’s wholly-owned intellectual property, the Control Flow HL2024 family of products which reduce water wastage and improve the performance of heating and hot water systems.

The Company’s main country of operation is the United Kingdom. The Company’s head office is based in London with additional offices in Leeds, Washington (Sunderland), India, Spain and the Netherlands. The Company has 168 employees, with the majority employed within the UK. Eneraqua Technologies has received the London Stock Exchange’s Green Economy Mark.

To find out more, please visit:  www.eneraquatechnologies.com

 

Cerillion (CER) interim results webinar

Monday, 20 May, 2:30pm
Register For Event

THIS EVENT HAS PASSED

Louis Hall, CEO, and Andrew Dickson, CFO, will discuss the Group’s half year performance and outlook, and there will be a question-and-answer session at the end of the presentation.

Cerillion plc is a United Kingdom-based billing, charging and customer relationship management (CRM) company. The principal activity of the Company is the supply and development of telecommunication software solutions and equipment. The Company operates through four segments: Services, Software, Software-as-a-Service and Third Party. The Services segment provides services to customers on new implementation projects and enhancements. The Software segment supports and provides maintenance of the software, as well as the licenses to use the software. The Software-as-a-Service segment offers monthly subscriptions for managed services or to use products on a right-to-use basis. The Third-Party segment provides third-party services or licenses, re-billable expenses, and pass through of selling hardware. The Company’s product categories include customer domain, product domain, sales domain, service domain, resource domain, and partner domain.

Subscribe to get notifications of our events

Click the subscribe button to be notified of any events we are running and also new videos

About PIWORLD

PIWORLD provides investors with the latest news and insight about listed companies and their management through either live or recorded investor presentations, management interviews, Capital Market Days and corporate overviews, together with interviews with leading fund managers or esteemed private investors in the small cap world.

Our Services

PIWORLD delivers high quality audio and video content to present anything from full-year & interim results to Capital Markets Days and corporate overviews. We bridge the gap between listed companies and the private investor community, who drive the share price and provide liquidity, providing a time and cost effective medium to reach this diverse and important audience.